Hengrui Advances SHR-8203 Into Phase 1/2 Study in Advanced Solid Tumors, With Filing Hinting at Potential PD-1/VEGF/CTLA-4 Trispecific
Chinese pharmaceutical giant Hengrui Pharma has registered a new clinical study of SHR-8203 injection on China’s drug trial registration platform, moving the previously undisclosed biologic into a multicenter Phase 1/2 trial in patients with…
HUTCHMED’s Savolitinib-Tagrisso Combo Delivers Positive Phase 3 Results in MET-Driven EGFR-Mutated NSCLC
HUTCHMED has announced positive topline results from the global Phase 3 SAFFRON trial, showing that the combination of ORPATHYS® (savolitinib) and TAGRISSO® (osimertinib) delivered statistically significant and clinically meaningful improvements in both…
iRegene secures another 260 million yuan in Series C+ financing to accelerate pipeline development
On July 2nd, iRegene Therapeutics announced the completion of a RMB 260 million Series C+ financing round. This round was led by Chengdu Science and Technology Venture Capital, with participation from CITIC Securities Capital, Xichuan Venture Capital,…
Henlius Expands Sandoz Partnership in Up to $322 Million Biosimilars Deal
Shanghai Henlius Biotech, Inc. (“Henlius”) has significantly expanded its partnership with Sandoz, entering a strategic collaboration covering up to 10 monoclonal antibody (mAb) and antibody-drug conjugate (ADC) biosimilar candidates in a…
MagicRNA raises hundreds of millions of yuan in Series B financing to advance world’s first in vivo CAR-T therapy
Recently, Shenzhen MagicRNA Biotechnology Co., Ltd. (or MagicRNA) announced the completion of a Series B financing round of several hundred million yuan. This round was led by a fund under CICC Capital, co-led by Kangjun Capital , with participation from…
Hopstem completes nearly 200 million yuan Series C financing to accelerate its core iPSC programs.
On August 10, 2026, Zhejiang Hopstem Biotechnology Co., Ltd. (or Hopstem) announced the completion of the first tranche of its nearly RMB 200 million Series C financing. This round of financing was jointly participated in by new shareholders Tasly…
Merck and InventisBio Ink a Partnership to Advance Clinical Development of Small-Molecule Cancer Drugs
August 10, 2026, Merck R&D (China) Co., Ltd. and InventisBio Co., Ltd. (or InventisBio), an innovative pharmaceutical company listed on the Science and Technology Innovation Board, simultaneously announced that they had signed a cooperation agreement…
BeiGene and Revolution Medicines Enter Strategic Collaboration
On August 10, BeiGene announced a multi-faceted collaboration agreement with Revolution Medicines. Under the agreement, the two companies will collaborate on clinical trials to jointly evaluate combination therapies of some of BeiGene’s…
Keymed completed Phase 2 trial of CM512, a TSLP x IL-13 bispecific antibody for chronic sinusitis
The Phase II clinical trial of long-acting TSLP x IL-13 bispecific antibody CM512 for the treatment of chronic sinusitis with nasal polyps (CRSwNP) has met all study endpoints.
GenFleet launches world’s first Phase 3 study of an oral KRAS G12D inhibitor for the treatment of NSCLC
GenFleet Therapeutics today held a national investigator conference for its Phase III registrational clinical trial of GFH375 (an oral KRAS G12D inhibitor) as monotherapy for non-small cell lung cancer (NSCLC) (“Kylin-Flight 01”). “Kylin-Flight 01” is a…